Abstract: A pharmaceutical dosage system comprising (a) an effective amount of one or more of Doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof; (b) an effective amount of one or more of (i) Pyridoxine, (ii) an analog thereof, (iii) a derivative thereof, (iv) a prodrug thereof, (v) a metabolite thereof and (vi) a salt of any of (i)-(v); and (c) an effective amount of one or more compounds of formula (I) wherein R is H, PO3? or The system exhibits an improved pharmacokinetic profile relative to the current Diclectin®/Diclegis® formulation and is useful for example for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting of pregnancy (NVP).
Abstract: This invention concerns the first environmentally benign heterogeneous modification of polysaccharide-based material in native solid state by thiol-ene “click chemistry”. The direct reaction of a thiol with an un-activated double or triple bond by thiol-ene and thiol-enyne click modification is thermally or photochemically catalyzed and is completely metal-free and allows for a highly modular approach to modifications of fibers and fiber-based materials.
Abstract: Described herein are macrolide and ketolide antibiotics and pharmaceutical compositions, methods, and uses thereof for treating gastrointestinal diseases.
Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof.
Type:
Grant
Filed:
March 19, 2013
Date of Patent:
September 13, 2016
Assignee:
Alios BioPharma, Inc.
Inventors:
Guangyi Wang, David Bernard Smith, Leonid Beigelman, Jerome Deval, Marija Prhavc
Abstract: A pharmaceutical dosage system comprising (a) an effective amount of one or more of Doxylamine, an analog thereof, a derivative thereof, a prodrug thereof, a metabolite thereof and/or a salt thereof; (b) an effective amount of one or more of (i) Pyridoxine, (ii) an analog thereof, (iii) a derivative thereof, (iv) a prodrug thereof, (v) a metabolite thereof and (vi) a salt of any of (i)-(v); and (c) an effective amount of one or more compounds of formula (I) wherein R is H, PO3- or The system exhibits an improved pharmacokinetic profile relative to the current Diclectin®/Diclegis® formulation and is useful for example for the alleviation of the symptoms of nausea and vomiting, for example in the case of nausea and vomiting of pregnancy (NVP).
Abstract: Bodily tissue and structures may be protected using a fluid layer containing a mixture of chitosan and oxidized polysaccharide. The mixture forms a protective gel layer via in situ crosslinking. Compared to crosslinking using a low molecular weight aldehyde such as glutaraldehyde or genipin, oxidized polysaccharides appear to provide faster gelation while avoiding the use of potentially less bioacceptable low molecular weight aldehydes.
Type:
Grant
Filed:
April 23, 2009
Date of Patent:
September 6, 2016
Assignee:
Medtronic, Inc.
Inventors:
Edze Jan Tijsma, Maria Nieves Gonzalez, Erica M. TenBroek, Nancy Schaffhausen
Abstract: An embodiment of the present disclosure provides a composition that includes hyaluronic acid, or its salt or derivative thereof, zinc citrate and an additive selected from the group consisting of grapefruit seed extract, Citricidal™, calcium propionate, sodium benzoate, potassium benzoate, magnesium citrate, proline, raddish root extract, Leucidal™ or 1,2-propanediol.
Abstract: Hsp90 C-terminal inhibitors and pharmaceutical compositions containing such compounds are provided. The compounds of the disclosure are useful for the treatment and/or prevention of neurodegenerative disorders such as diabetic peripheral neuropathy.
Type:
Grant
Filed:
February 8, 2013
Date of Patent:
August 23, 2016
Assignee:
UNIVERSITY OF KANSAS
Inventors:
Brian S. J. Blagg, Bhaskar Reddy Kusuma, Teather Sundstrom
Abstract: Covalently modified alginate polymers, possessing enhanced biocompatibility and tailored physiochemical properties, as well as methods of making and use thereof, are disclosed herein. The covalently modified alginates are useful as a matrix for the encapsulation and transplantation of cells. Also disclosed are high throughput methods for the characterizing the biocompatibility and physiochemical properties of modified alginate polymers.
Type:
Grant
Filed:
June 4, 2012
Date of Patent:
August 23, 2016
Assignee:
Massachusetts Institute of Technology
Inventors:
Arturo J. Vegas, Minglin Ma, Kaitlin M. Bratlie, Daniel G. Anderson, Robert S. Langer
Abstract: The present invention relates to a method for producing an alkali cellulose with suppressed decrease in the degree of polymerization as well as with small use amount of a basic compound, and to a method for producing a cellulose ether by using the alkali cellulose thus obtained. Provided by the present invention are: (A) a method for producing an alkali cellulose, comprising Step 1 wherein a cellulose-containing raw material (I) is treated by a pulverizing machine thereby obtaining a cellulose-containing raw material (II) which contains a cellulose having crystallinity in the range of 10 to 55% and Step 2 wherein the cellulose-containing raw material (II) obtained in Step 1 is added by a basic compound with the amount thereof being in the range of 0.6 to 1.
Abstract: The present invention relates to a method for producing an alkali cellulose with suppressed decrease in the degree of polymerization as well as with small use amount of a basic compound, and to a method for producing a cellulose ether by using the alkali cellulose thus obtained. Provided by the present invention are: (A) a method for producing an alkali cellulose, comprising Step 1 wherein a cellulose-containing raw material is pulverized in the presence of 0.6 to 1.
Abstract: Provided is a method of treating a saccharide-containing composition, the method comprising contacting a composition containing a saccharide with a compound of formula (I) or a salt thereof wherein R1-R4, X, and n are as described herein. Further provided is a composition comprising a saccharide and a compound of formula (I) or a salt thereof.
Abstract: The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions which are particularly advantageous for correction of fine lines in the face.
Type:
Grant
Filed:
September 13, 2012
Date of Patent:
August 9, 2016
Assignee:
Allergan, Inc.
Inventors:
Gabriel N. Njikang, Futian Liu, Xiaojie Yu, Nicholas J. Manesis, Sumit Paliwal
Abstract: A (meth)allylsilane compound chemically bonded to various alcohol derivatives including polyol derivatives such as saccharides, is raw material used to cause a substrate to express functionalities such as a defogging property and separation characteristics for column chromatography, can be easily prepared, is easily purified, and is stable and easy to handle, and a functional material in which those functionalities are expressed, while silyl group-containing groups are conveniently carried at a high density on the surface of the substrate, by using the (meth)allylsilane compound as a silane coupling agent for silane-coupling to the substrate. The (meth)allylsilane compound includes a (meth)allylsilyl group-containing alkyl group or a (meth)allylsilylalkyl group-containing aralkyl group that is bonded to an alcohol derivative.
Type:
Grant
Filed:
June 28, 2012
Date of Patent:
August 9, 2016
Assignees:
KYOEISHA CHEMICAL CO., LTD., DAICEL CORPORATION
Abstract: Methods and small molecule compounds for inhibition of cancer cell proliferation are provided. One example of a class of compounds that may be used is represented by the compound of Formula I or a pharmaceutically acceptable salt, N-oxide or solvate thereof, wherein A, B, D, E, F, G, I, J, R, R1, R2, R2?, R3, R4, R5, R6, R7, R8, R9 are as described herein.
Type:
Grant
Filed:
January 24, 2013
Date of Patent:
August 2, 2016
Assignee:
ChemRegen, Inc.
Inventors:
John Cashman, Mark Mercola, Dennis Schade, Masanao Tsuda
Abstract: The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction ratio of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction ratio as that of the conventionally known gel.
Type:
Grant
Filed:
July 22, 2013
Date of Patent:
July 19, 2016
Assignee:
CHUGAI SEIYAKU KABUSHIKI KAISHA
Inventors:
Kenji Yasugi, Teruo Nakamura, Tsuyoshi Shimoboji, Mika Sato
Abstract: The present invention relates to ivermectin formulations for administration to pet and domestic animals. These formulations provide long term protection against Dirofilaria parasites, without the risks for secondary adverse of conventional formulations. Preferred formulations are collars, collar strips, or medallions, attachments for collars, ear tags, bands which are affixed to limbs or parts of the body, adhesive strips and films, and peel-off films, or spot-on or pour-on forms which are administered at least twice a year up to around once a year.
Type:
Grant
Filed:
July 29, 2011
Date of Patent:
July 19, 2016
Assignee:
CEVA SANTA ANIMALE
Inventors:
Patrick Forget, Vassilios Kaltsatos, Stephan Warin
Abstract: Compounds having the general structural formula (I) wherein X can be any element or compound that can form a coordination complex with phthalocyanine and wherein R1; R2, R3 and R4 are independently anionic moieties, or (II) wherein R1; R2, R3 and R4 are independently anionic moieties, are useful in the potentiation of antibiotic activity, and/or in inhibiting or delaying the development of resistance to antibiotics. R1; R2, R3 and R4 may be —S03-. The compounds may be administered to a subject in conjunction with an antibiotic. The antibiotic may be an activator of the SOS response, and may be a DNA gyrase inhibitor or a topoisomerase inhibitor. Compositions and dosage forms comprising the compounds are provided.
Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs for parenteral administration. Also provided are methods of preparing the compositions and methods of treating diseases and disorders using the compositions provided herein.
Type:
Grant
Filed:
January 31, 2012
Date of Patent:
July 19, 2016
Assignee:
Celgene Corporation
Inventors:
Anthony Tutino, Mei Lai, Jeffrey B. Etter